Several preclinical studies have now demonstrated that targeting CAIX activity with SLC-0111 results in anti-tumour efficacy in multiple solid tumour models, including including triple negative breast cancer (Lou et al., 2011; Lock et al., 2013; Chafe et al., 2015; Bozdag et al., 2018; Hedlund et al., 2019), pancreatic cancer (McDonald et al., 2019) and melanoma (Chafe et al., 2019). Here, CA9 is linked to triple-negative breast carcinoma.